BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
February 26, 2016 9:46 AM EST
Piper Jaffray analyst, Joshua Schimmer, sees numerous catalysts for BioMarin (NASDAQ: BMRN) as the company marches toward profitability. No change to Overweight rating but the PT is revised down to $107.
BMRN has spent years with aggressive opex and burning cash on a promising pipeline. But much of that pipeline is now close to graduating towards commercial products and it's time for the company to move towards generating cash flows for investors while also finding new programs to replace... More
February 25, 2016 4:04 PM EST
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.39, $0.60 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $224.38 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.05-1.10 billion, versus the consensus of... More
